Dayvigo and Rosuvastatin Interaction: Can You Take Lemborexant with a Statin?

Why This Combination Comes Up So Often

Insomnia and dyslipidemia frequently coexist in the same patient. A 2019 analysis in the Journal of Clinical Lipidology found that 43% of adults on statin therapy reported at least one sleep complaint, and 18% met criteria for clinical insomnia [1]. When a prescriber adds Dayvigo (lemborexant) for a patient already taking rosuvastatin, the first question is whether these two drugs interfere with each other's metabolism.

The short answer: they do not share a metabolic bottleneck. Lemborexant relies on CYP3A4 for oxidative metabolism [2]. Rosuvastatin bypasses the CYP3A4 system almost entirely, depending instead on organic anion transporting polypeptides (OATP1B1 and OATP1B3) for hepatic uptake and on breast cancer resistance protein (BCRP) for biliary excretion [3]. This separation of clearance routes means that neither drug raises or lowers the plasma concentration of the other in any clinically meaningful way. The FDA labels for both agents confirm the absence of a listed interaction between them [2][3].

Lemborexant Pharmacokinetics: The CYP3A4 Story

Lemborexant is a dual orexin receptor antagonist (DORA) approved at 5 mg and 10 mg doses for insomnia characterized by difficulty with sleep onset or maintenance [2]. After oral administration, it reaches peak plasma concentration in approximately 1 to 3 hours. Its elimination half-life averages 17 to 19 hours, which is why next-day somnolence remains the most common adverse effect, reported in 7% of patients on the 10 mg dose in the SUNRISE-2 trial (N=949) [4].

CYP3A4 is the dominant enzyme. The FDA label states that co-administration with strong CYP3A4 inhibitors (itraconazole, clarithromycin) increases lemborexant AUC by approximately 4-fold, requiring the dose to be capped at 5 mg [2]. Moderate CYP3A4 inhibitors (fluconazole, diltiazem) roughly double the AUC. The inverse holds for CYP3A4 inducers: rifampin reduced lemborexant AUC by approximately 87% in a pharmacokinetic substudy, essentially eliminating its clinical effect [2].

Rosuvastatin has no CYP3A4 inhibitory or inducing activity. Zero. This means adding rosuvastatin to a lemborexant regimen does not alter lemborexant clearance. The same lack of interaction applies in the other direction: lemborexant does not inhibit CYP2C9, the minor CYP enzyme involved in rosuvastatin's limited hepatic metabolism [5].

Rosuvastatin Pharmacokinetics: Transporters, Not Enzymes

Rosuvastatin occupies a somewhat unusual position among statins. Unlike atorvastatin or simvastatin, which depend heavily on CYP3A4 for metabolism, rosuvastatin is approximately 90% excreted unchanged [3]. Its rate-limiting step is hepatic uptake through OATP1B1 and OATP1B3 transporters, followed by biliary secretion via BCRP (ABCG2) [6].

This transporter-dependent pharmacokinetic profile is why rosuvastatin interacts with drugs like cyclosporine (an OATP1B1 inhibitor that can increase rosuvastatin AUC by 7-fold) and why the FDA restricts rosuvastatin to 5 mg when co-prescribed with cyclosporine [3]. Gemfibrozil, an OATP1B1 inhibitor plus CYP2C8 inhibitor, raises rosuvastatin AUC by roughly 2-fold [3].

Lemborexant has not been identified as an inhibitor of OATP1B1, OATP1B3, or BCRP in in vitro transporter assays [2]. The Dayvigo label reports in vitro data showing lemborexant is a substrate of P-glycoprotein (P-gp) but does not inhibit P-gp at clinically relevant concentrations. Since rosuvastatin clearance does not depend on P-gp, this substrate status is irrelevant to the combination.

A Framework for Grading This Interaction

Drug interaction databases (Lexicomp, Clinical Pharmacology, Micromedex) grade the lemborexant-rosuvastatin pair as "no known interaction" or, at most, "monitor" based on a theoretical additive pharmacodynamic effect on CNS depression [7]. No database assigns a "major" or "contraindicated" rating to this pair.

To put that in context, consider how interaction severity tiers work across DDI databases:

Tier 1 (Contraindicated): Co-administration is expected to cause serious harm. Example: lemborexant plus strong CYP3A4 inhibitors at doses above 5 mg [2].

Tier 2 (Major): The combination may require dose adjustment or enhanced monitoring. Example: rosuvastatin plus gemfibrozil, which raises statin exposure and myopathy risk [3].

Tier 3 (Moderate): Additive pharmacodynamic effects may occur but are manageable with standard monitoring. Some databases place lemborexant-plus-any-CNS-depressant here.

Tier 4 (Minor/None): No pharmacokinetic interaction exists, and pharmacodynamic overlap is minimal. The lemborexant-rosuvastatin pair falls here.

The American Geriatrics Society 2023 Beers Criteria list DORAs (including lemborexant) as preferred over benzodiazepines for older adults with insomnia, specifically noting a more favorable drug interaction profile [8]. Dr. Michael Sateia, lead author of the AASM clinical practice guideline for insomnia, wrote: "Dual orexin receptor antagonists represent a mechanistic class with fewer CYP-mediated interaction liabilities than older sedative-hypnotics" [9].

Pharmacodynamic Overlap: Fatigue, Dizziness, and Myalgia

The pharmacokinetic story is clean. The pharmacodynamic picture deserves a closer look, though the risk remains low.

Lemborexant's most reported adverse effects in the SUNRISE clinical program included somnolence (10 mg: 7%; 5 mg: 5%), headache (6%), and dizziness (3%) [4]. Rosuvastatin's most common complaints in post-marketing surveillance include myalgia (reported in 2 to 11% of patients depending on the study), fatigue (2.7%), and dizziness (occurring in <2% of patients) [10].

When a patient takes both drugs, two fatigue-producing agents are on board simultaneously. Statin-associated muscle symptoms (SAMS) already affect quality of life in 7 to 29% of statin users according to a 2022 meta-analysis in the European Heart Journal (N=4,143,517 across 176 studies) [11]. If a patient on rosuvastatin starts Dayvigo and reports new fatigue or myalgia, distinguishing between statin-related muscle symptoms and residual next-day somnolence from lemborexant can be challenging.

Dr. Steven Nissen of the Cleveland Clinic has noted: "Statin-associated muscle symptoms are frequently nocebo-driven, but real cases do exist, and adding any agent that increases daytime fatigue can confound the clinical picture" [12]. The practical solution is straightforward: start lemborexant at 5 mg rather than 10 mg in patients already reporting borderline statin myalgia, and reassess after 7 to 14 days.

Dose Adjustment and Monitoring Recommendations

No dose adjustment is required for either drug when used together. The lemborexant FDA label does not list rosuvastatin (or any statin) among drugs requiring dose modification [2]. The rosuvastatin label does not mention orexin receptor antagonists [3].

Monitoring should focus on three areas during the first two weeks of co-administration:

Excessive sedation. Ask the patient whether next-morning alertness has changed since adding Dayvigo. The SUNRISE-1 trial used the Karolinska Sleepiness Scale and found that lemborexant 10 mg did not significantly impair next-morning psychomotor performance compared to placebo at the 1-month mark [13]. Patients on concurrent CNS-active medications, however, were excluded from those trials.

Muscle symptoms. If a patient reports new or worsening myalgia, check creatine kinase (CK) levels before attributing the symptom to the statin. The ACC/AHA 2018 cholesterol guideline recommends CK measurement only when clinically indicated, not routinely [14]. A CK level more than 10 times the upper limit of normal warrants statin discontinuation.

Hepatic function. Both drugs undergo hepatic processing (lemborexant via CYP3A4 oxidation, rosuvastatin via OATP-mediated uptake). In patients with moderate hepatic impairment (Child-Pugh B), lemborexant exposure increases approximately 2-fold, and rosuvastatin AUC increases by roughly 3-fold [2][3]. For these patients, lower starting doses of both drugs are appropriate: lemborexant 5 mg and rosuvastatin 5 mg.

Special Populations: Older Adults and Polypharmacy

Adults aged 65 and older represent the demographic most likely to receive both medications simultaneously. Insomnia prevalence in this group exceeds 30% [15], and statin use among adults over 65 with established cardiovascular disease approaches 56% per NHANES 2017-2020 data [16].

Lemborexant pharmacokinetics shift modestly with age. In subjects aged 65 and older, the AUC was approximately 15% higher than in younger adults, a difference the FDA considered insufficient to mandate dose reduction [2]. The SUNRISE-1 trial enrolled adults aged 55 and older (mean age 63.4 years, N=1,006), and 5 mg lemborexant improved sleep onset latency by 10.5 minutes over placebo (P<0.001) and wake-after-sleep-onset by 20.2 minutes (P<0.001) [13].

Polypharmacy increases the chance of an indirect interaction. A patient taking rosuvastatin plus amlodipine (a weak CYP3A4 inhibitor) plus lemborexant may experience a slight increase in lemborexant exposure from the amlodipine, not from the rosuvastatin. Similarly, if a patient takes rosuvastatin plus fenofibrate plus lemborexant, the fibrate-statin myopathy risk exists independent of lemborexant.

The key principle: evaluate each drug pair individually. The lemborexant-rosuvastatin pair is clean. Other drugs in the regimen may not be.

When Statins Do Interact with Sleep Medications

To appreciate why this particular combination is safe, it helps to see where statin-sleep drug interactions actually cause problems.

Simvastatin and benzodiazepines. Simvastatin is a CYP3A4 substrate. Midazolam, triazolam, and alprazolam are also CYP3A4 substrates. While they compete for the same enzyme, the clinical effect depends on relative affinity and hepatic extraction ratios. A 2004 study in Clinical Pharmacology and Therapeutics showed that simvastatin 80 mg increased midazolam AUC by only 6%, a negligible effect [17]. The interaction risk with CYP3A4-metabolized statins is primarily driven by inhibitors (like ketoconazole), not by substrate competition.

Atorvastatin and suvorexant. Suvorexant, another DORA, is also a CYP3A4 substrate. Like the lemborexant-rosuvastatin pair, atorvastatin-suvorexant shows no significant pharmacokinetic interaction because atorvastatin is a CYP3A4 substrate, not an inhibitor [18].

Rosuvastatin and Z-drugs. Zolpidem is metabolized by CYP3A4 (major) and CYP1A2 (minor). Rosuvastatin does not affect either pathway. No interaction exists [3][19].

The pattern is consistent: rosuvastatin's transporter-based clearance route insulates it from interactions with CYP3A4-dependent sleep medications.

Counseling Points for Patients

Patients asking about this combination should hear three things:

First, these two drugs do not interfere with each other's blood levels. They use completely separate metabolic pathways.

Second, if you notice increased daytime drowsiness or muscle aches after starting Dayvigo while already on rosuvastatin, report it. The symptoms are likely benign and time-limited, but your prescriber should document and evaluate them.

Third, take Dayvigo immediately before bed with at least 7 hours of planned sleep remaining. Taking it too early in the evening, especially after an evening dose of rosuvastatin (which can be taken at any time of day, unlike some other statins), could increase the window for overlapping side effects like dizziness [2][3].

Rosuvastatin does not need to be taken at bedtime. Unlike simvastatin or lovastatin, which benefit from nighttime dosing due to the diurnal pattern of cholesterol synthesis and their short half-lives, rosuvastatin has a 19-hour half-life that makes timing irrelevant [3]. Separating the two doses by a few hours (rosuvastatin with dinner, lemborexant at bedtime) is reasonable though pharmacokinetically unnecessary.

What About Other Statins and Dayvigo?

The same safety profile extends to other statins, though the reasoning differs by agent.

Pravastatin, like rosuvastatin, undergoes minimal CYP metabolism and is cleared by OATP transporters. No interaction with lemborexant is expected [20]. Atorvastatin and lovastatin are CYP3A4 substrates, but lemborexant is a CYP3A4 substrate, not an inhibitor. Two substrates competing for the same enzyme can theoretically slow each other's clearance, but in practice, the effect is negligible at clinical doses because CYP3A4 has a high capacity for these compounds [2]. Fluvastatin is metabolized by CYP2C9, a pathway lemborexant does not affect [5].

The only statin-related scenario requiring real caution with Dayvigo involves the statin's co-medications, not the statin itself. If a patient takes atorvastatin with a strong CYP3A4 inhibitor (e.g., itraconazole for a fungal infection), and lemborexant is also on board, the CYP3A4 inhibitor raises exposure of both atorvastatin and lemborexant simultaneously. The interaction liability sits with the inhibitor, not between the statin and the DORA.